Use of electroacupuncture (EA) â€“ a form of acupuncture where a small electric current is passed between pairs of acupuncture needles â€“ produces significant improvements in fatigue, anxiety and depression in as little as eight weeks for early stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors (AIs) to treat breast cancer. The results of a randomized, placebo-controlled trial examining the intervention led by researchers at the Perelman School of Medicine at the University of Pennsylvania are published online this week in the journal Cancer. The study is the first demonstration of EAâ€™s efficacy for both joint pain relief, as well as these other common symptoms.
The results build upon earlier findings reported in November 2013, showing that EA can decrease the joint pain reported by roughly 50 percent of breast cancer patients taking AIs â€“ the most-commonly prescribed medications to prevent disease recurrence among post-menopausal women with early-stage, hormone receptor positive breast cancer. Despite their efficacy, the joint pain associated with the use of AIs often leads to fatigue, anxiety, depression, and sleep disturbances for these patients, which researchers suggest may cause premature discontinuation of the drug. Previous studies have shown that nearly half of women taking AIs do not complete their recommended course of treatment, and that those who stop taking the drugs or donâ€™t take them as prescribed have a higher chance of dying of both breast cancer and other causes.
â€śSince many patients experience pain, fatigue, anxiety and depression simultaneously, our results provide an opportunity to offer patients one treatment that may target multiple symptoms,â€ť said lead author Jun Mao, MD MSCE, associate professor of Family Medicine and Community Health in Pennâ€™s Perelman School of Medicine, who directs the Integrative Oncology program in the Abramson Cancer Center. â€śWe see patients every day who are looking for ways to combat some of the side effects of their treatment. What is particularly significant about these new results is that we can now offer more evidence-based treatment and management solutions for these women.
Click here to read full release.